SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.

(6826)
  Report
Delayed Hong Kong Stock Exchange  -  05/17 04:08:55 am EDT
31.85 HKD   +1.11%
04/29Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/28Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021
CI
02/27Haohai Biological Technology Posts Higher Earnings in 2021
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Tranche Update on Shanghai Haohai Biological Technology Co., Ltd.'s Equity Buyback Plan announced on July 21, 2020.

08/26/2021 | 08:24am EDT

From January 1, 2021 to June 11, 2021, the company has repurchased 800,000 shares, representing 0.45% for HKD 53.7 million. With this, the company has completed the repurchase of 1,384,500 shares, representing 0.78% for HKD 84.94 million under the buyback announced on July 21, 2020.


ę S&P Capital IQ 2021
All news about SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
04/29Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the First ..
CI
03/28Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for th..
CI
02/27Haohai Biological Technology Posts Higher Earnings in 2021
MT
02/27Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Full Y..
CI
01/31Haohai Biological Technology Projects up to 65% Jump in 2021 Profit
MT
01/28Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for th..
CI
2021Shanghai Haohai Biological Technology Co., Ltd. commences an Equity Buyback Plan for 3,..
CI
2021SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : 688366) added to Shanghai Stock Exchange Health Car..
CI
2021Haohai Biological Buys 51% Stake in Contact Lens Maker for $11 Million
MT
2021Shanghai Haohai Biological Technology's Q3 Profit Drops 6.6% as R&D Expenses Rise
MT
More news
Financials
Sales 2022 2 197 M 324 M 324 M
Net income 2022 498 M 73,4 M 73,4 M
Net cash 2022 3 433 M 506 M 506 M
P/E ratio 2022 9,77x
Yield 2022 2,95%
Capitalization 11 679 M 1 721 M 1 721 M
EV / Sales 2022 3,75x
EV / Sales 2023 3,09x
Nbr of Employees 1 892
Free-Float 38,1%
Chart SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Duration : Period :
Shanghai Haohai Biological Technology Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 27,22 CNY
Average target price 56,61 CNY
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Jian Ying Wu General Manager & Director
Min Jie Tang Chief Financial Officer & Executive Director
Yong Tai Hou Chairman
Yuan Zhong Liu Chairman-Supervisory Board
Chang Zheng Wei Deputy Manager-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.-38.84%1 721
ABBOTT LABORATORIES-22.05%192 096
MEDTRONIC PLC0.35%139 265
BECTON, DICKINSON AND COMPANY2.90%72 090
BAXTER INTERNATIONAL INC.-14.15%37 105
HOYA CORPORATION-25.51%36 034